Vimarsana
Biggest News Aggregation in the World

Page 49 - Contract Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Contract Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Contract Development Today - Breaking & Trending Today

Strides Pharma falls 5% from 52-week highs on spin off of CDMO - Vimarsana News

Strides Pharma falls 5% from 52-week highs on spin off of CDMO

Strides Pharma shareholders would receive 1 share of OneSource for every 2 shares of Strides in the swap ratio of 1:2

Strides Pharma demerger: Strides Pharma to spin off contract development unit - Vimarsana News

Strides Pharma demerger: Strides Pharma to spin off contract development unit

Strides Pharma Science on Monday said it would spin off its contract development and manufacturing organisation (CDMO) and soft gelatin business into a new entity which would list in the next 12-16 months.

Strides Pharma to spin off CDMO, soft gelatin biz into OneSource; listing expected in 12 months - Vimarsana News

Strides Pharma to spin off CDMO, soft gelatin biz into OneSource; listing expected in 12 months

Demerger will be completed by April 1, 2024 according to the stock exchange filing

Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference - Vimarsana News

Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference

SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will participate at the RBC Capital Markets Virtual CDMO Conference. David Enloe, chief executive officer, will be the featured speaker in a fireside

Source: yahoo.com
Nirma's acquisition of majority stake in Glenmark Life Sciences to make Glenmark Pharma debt-free - Vimarsana News

Nirma's acquisition of majority stake in Glenmark Life Sciences to make Glenmark Pharma debt-free

Glenmark Pharmaceuticals has entered into a share purchase agreement with Nirma Limited to divest a 75% stake in Glenmark Lifesciences at a price of Rs 615 per share.